As was expected, ncRNA PANC754 increases the immune therapeutics ability of this anti-NKG2A ICI by improving the release of Perforin to CRC cells (Fig. 7B), the solid evidence is that the increasing concentration of LDH after PANC754 and Monalizumab combination therapy (Fig. 7D). This evidence concerns the gene KLRC1 and colorectal carcinoma.